ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

How Mutation Status Affects Individualization of Treatment in mCRC

Maria Ignez Braghiroli, MD
Published Online:5:53 PM, Fri October 28, 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.